Auris Medical (EARS) Stock Heads For The Top On Positive Data

Auris Medical EARS Stock New

Auris Medical Holding Ltd (NASDAQ: EARS) is flying in the market this morning, and for good reason. The company announced positive results from a clinical trial, exciting investors. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

EARS Stock Heads For The Top On Clinical Data

In the press release, Auris Medical announced positive top-line data from the interim analysis of a Phase 2 trial. The trial, known as TRAVERS, is assessing the company’s intranasal betahistine in vertigo patients.

In the release, the company said that the treatment has demonstrated dose-dependent improvement in balance as well as favorable safety and tolerability. These results were seen through ascending doses of AM-125.

In a statement, Thomas Meyer, founder, Chairman and CEO at EARS, had the following to offer:

We are very excited and encouraged by the good safety and tolerability as well as the strong and consistent signals of AM-125’s clinical efficacy observed in this first part of the TRAVERS trial.

For patients suffering from vertigo, regaining balance as quickly as possible is of utmost importance. Unlike other vertigo drugs that suppress the vestibular function to treat just short-term symptoms such as nausea, AM-125 acts as a vestibular stimulant to enhance and accelerate vestibular compensation and help patients to ‘get back on their feet’. There is a strong medical need for a novel drug in this area, with e.g. 35.4% of the US population aged 40 years and older suffering from vestibular dysfunction (i.e. failing the “Standing on Foam” test).1 We look forward to advancing the AM-125 program further in order to bring this innovative nasal spray to patients.

This News Is Huge

The news issued by Auris Medical this morning is overwhelmingly positive. It shows that the company’s lead clinical candidate is advancing well, and data from a mid-stage clinical trial is positive.

Should data continue to be so positive, the company will likely push for a Phase 3 trial relatively soon and market approval. This brings out massive potential for EARS and its investors.

The vertigo market is a huge one. It is expected that the market will grow to be worth nearly $1 billion a year by 2023. For a company with a sub $8 million market cap, the opportunity here is tremendous, making EARS stock one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.